Stereotactic radiotherapy plus chemotherapy with a TP regimen significantly optimizes the clinical efficacy of the NSCLC treatment, enhances the quality of life of patients, and mitigates the serum CYFRA21-1 and MALAT1 levels, with a high safety profile. This evidence concerns the gene MALAT1 and non-small cell lung carcinoma.